Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. DSGN
DSGN logo

DSGN

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

DSGN News

Design Therapeutics Q4 Earnings Beat Expectations

1d agoseekingalpha

FibroBiologics (FBLG) Stock Rises 7.68%, Attracts Market Attention

Jan 13 2026NASDAQ.COM

Significant Options Trading on Wednesday: UTHR, URGN, DSGN

Dec 17 2025NASDAQ.COM

Design Therapeutics to Participate in Two Investor Conferences

Nov 26 2025Globenewswire

Nutex Health Reports Impressive Q3 Performance, Partners with PACS Group, While Walmart, Cerence, and Other Major Stocks Rise on Thursday

Nov 20 2025Benzinga

Steven Cohen's Biotech Investments Are Becoming More Ambitious Yet More Focused

Aug 29 2025Benzinga

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

Apr 21 2025Yahoo Finance

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Apr 16 2025Globenewswire

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 10 2025Newsfilter

Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Dec 31 2024Benzinga

Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Dec 31 2024Benzinga

Lamb Weston Posts Weak Q2 Results, Joins Micron, Lennar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Dec 19 2024Benzinga

Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Dec 19 2024Benzinga

Design Therapeutics GAAP EPS of -$0.23 beats by $0.02

Nov 08 2024SeekingAlpha

Larimar stock rallies 24% on FDA removal of partial clinical hold

May 20 2024SeekingAlpha

DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024

May 09 2024Business Insider